18 completed, 10 recruiting, 7 unknown, 5 active not recruiting. 12 Phase 2, 11 Not applicable, 8 Phase 3, 4 Phase 1, 1 Phase 4.
Follow Prostate Cancer Recurrent: new trials by email Literature Review of Prostate Cancer Recurrent trials Research Report on Prostate Cancer Recurrent
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3 - Prostate Cancer, Recurrent Prostate Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 20 | 2026-10-31 | 2026-09-11 |
| 18F-PSMA PET/CT Versus CT Alone in Assessment of Prostatic Cancer Patients Prostate Cancer, Prostate Cancer Metastatic | Not yet recruiting | Assiut University | 59 | 2026-05-01 | 2026-03-20 | |
| Social, Structural, and Lifestyle Drivers of Prostate Cancer Disparities Questionnaires, Medical Record Review - Prostate Cancer, Prostate Cancer Recurrent | Recruiting | University of California, San Francisco | 350 | 2026-03-31 | 2026-07-08 | |
| Lab Research Using Mini-tumors to Study Prostate Cancer Treatments HDR brachytherapy, Diagnostic biopsy - Prostate Cancer, Prostate Cancer Metastatic Disease | Recruiting | Maastricht Radiation Oncology | 600 | 2026-03-15 | 2026-04-23 | |
| Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy fezolinetant - reference formulation, Placebo - Prostate Cancer, Prostate Cancer (Adenocarcinoma) | Phase 2 | Recruiting | Shehzad Basaria, M.D. | 60 | 2026-01-14 | 2026-08-17 |
| Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy Prostate Cancer (Diagnosis), Prostate Cancer Patients Who Have Brachytherapy Seed Implant | Recruiting | University of Erlangen-Nürnberg Medical School | 200 | 2025-12-01 | 2025-11-18 | |
| 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer 64Cu-SAR-bisPSMA - Prostate Cancer, Prostate Cancer Patients With Detectable PSA Following Prostatectomy | Phase 3 | Active not recruiting | Clarity Pharmaceuticals Ltd | 220 | 2025-05-16 | 2026-05-14 |
| A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment INR101 - Prostate Cancer Recurrent | Phase 3 | Not yet recruiting | Yunhe Pharmaceutical (Tianjin) Co., Ltd | 110 | 2025-04-01 | 2025-04-11 |
| Using Meditation for Oncology Anxiety Mantra Meditation - Anxiety, Quality of Life | Not applicable | Withdrawn | Mellar Davis MD | 2025-01-31 | 2024-10-08 | |
| Salvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed Recurrence After Radiotherapy in the PSMA PET Scan Era High Dose Rate Brachytherapy - Prostate Cancer Recurrent, Prostate Cancer | Not applicable | Recruiting | University Health Network, Toronto | 20 | 2024-08-08 | 2026-10-20 |
| PSMA-RLT in Biochemically Recurrent PCa [177Lu]Lu-PSMA I&T - Prostate Cancer Recurrent | Phase 2 | Recruiting | Medical University of Vienna | 20 | 2024-01-15 | 2024-02-13 |
| A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer lorigerlimab, docetaxel, Prednisone - Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms | Phase 2 | Completed | MacroGenics | 154 | 2023-09-28 | 2026-05-22 |
| Antibody CC-1 in Men With Biochemical Recurrence of Prostate Cancer CC-1 Infusion - Prostate Cancer Recurrent | Phase 1 | Recruiting | University Hospital Tuebingen | 56 | 2022-11-11 | 2024-05-16 |
| Metastasis-directed Therapy for Oligorecurrent Prostate Cancer Radiotherapy (SBRT) and/or surgery (metastasectomy), Androgen deprivation therapy, Androgen receptor targeted therapy - Prostate Cancer, Prostate Cancer Recurrent | Phase 3 | Recruiting | Universitaire Ziekenhuizen KU Leuven | 873 | 2022-04-20 | 2024-07-03 |
| COAST Therapy in Advanced Solid Tumors and Prostate Cancer Hydroxychloroquine, Metformin, Sirolimus, Hydroxychloroquine, Metformin, Sirolimus, Dasatanib, Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir - Prostate Cancer Recurrent, Solid Tumor, Adult | Phase 1 / Phase 2 | Recruiting | Medical University of South Carolina | 76 | 2022-03-03 | 2026-05-13 |
| Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer [18F]PSMA-1007 - Prostate Cancer, Prostate Cancer Recurrent | Phase 3 | Completed | ABX advanced biochemical compounds GmbH | 136 | 2021-08-27 | 2025-07-15 |
| MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer MBM-02 - Prostate Cancer Recurrent, Biochemical Recurrent Prostate Cancer | Phase 2 | Unknown | Matrix Biomed, Inc. | 55 | 2021-05-30 | 2021-05-06 |
| An AI Platform Integrating Imaging Data and Models, Supporting Precision Care Through Prostate Cancer's Continuum Magnetic Resonance Imaging - Prostate Cancer, Prostate Cancer Metastatic | Completed | Fondazione del Piemonte per l'Oncologia | 14000 | 2021-02-24 | 2026-06-04 | |
| Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer Darolutamide, metastasis-directed treatment - Prostate Cancer, Prostate Cancer Recurrent | Phase 2 | Unknown | University Hospital, Ghent | 124 | 2021-02-12 | 2024-02-28 |
| PSMA Guided Approach for bIoCHEmical Relapse After Prostatectomy-PSICHE Prostate Cancer, Biochemical Relapse Fo Malignant Neoplasm of Prostate | Recruiting | Azienda Ospedaliero-Universitaria Careggi | 180 | 2021-01-19 | 2021-08-26 |
Showing 20 of 47. Sign in to see all of them.
Prostatic Neoplasms (31) · Disease (3) · Neoplasm Metastasis (3) · Adenocarcinoma (1) · Anxiety Disorders (1) · Hot Flashes (1) · Lymphatic Metastasis (1) · Multiple Endocrine Neoplasia Type 1 (1) · Prostate Cancer, Hereditary, 7 (1) · Prostatic Diseases (1) · Prostatic Neoplasms, Castration-Resistant (1) · Recurrence (1)
Genital Diseases (32) · Genital Diseases, Male (32) · Genital Neoplasms, Male (32) · Male Urogenital Diseases (32) · Neoplasms (32) · Neoplasms by Site (32) · Urogenital Diseases (32) · Urogenital Neoplasms (32) · Prostatic Diseases (31) · Pathological Conditions, Signs and Symptoms (9) · Pathologic Processes (8) · Neoplastic Processes (4) · Carcinoma (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Disease Attributes (1)
gallium 68 PSMA-11 (3) · Hydroxychloroquine (2) · Metformin (2) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (2) · 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (1) · 68 Ga-P16-093 (1) · Androgen Antagonists (1) · Blood Specimen Collection (1) · Dasatinib (1) · Diet, Protein-Restricted (1) · Docetaxel (1) · Gonadotropins (1) · Magnetic Resonance Imaging (1) · Magnetic Resonance Spectroscopy (1) · Metastasectomy (1)
ABX advanced biochemical compounds GmbH (2) · Medical University of Vienna (2) · Assiut University (1) · Azienda Ospedaliero-Universitaria Careggi (1) · Canadian Urology Research Consortium (1) · Centre for Probe Development and Commercialization (1) · Clarity Pharmaceuticals Ltd (1) · Curium PET France (1) · Dana Mathews (1) · Five Eleven Pharma, Inc. (1) · Fondazione del Piemonte per l'Oncologia (1) · Hellenic Cooperative Oncology Group (1) · Hospices Civils de Lyon (1) · Indiana University (1) · Institut Cancerologie de l'Ouest (1)
United States (18) · Canada (5) · France (5) · Belgium (4) · Germany (4) · Netherlands (3) · United Kingdom (3) · Australia (2) · Austria (2) · China (2) · Italy (2) · Sweden (2) · Switzerland (2) · Bulgaria (1) · Denmark (1)
Aaron E Katz, MD (1) · Andrea Sottoriva, BSc MSc PhD (1) · Anna-Jasmina Donaubauer, Dr. rer. nat. (1) · Claudia Schweizer, MD (1) · Daniel R Zwahlen, MD (1) · Elena Fountzila (1) · Evert J Van Limbergen, PhD, MD (1) · Hans Chung, MD (1) · Hongcheng Shi (1) · Hongliang Fu, MD (1) · James Nagarajah, MD, PhD (1) · Jeong Yeon Cho, MD (1) · Jessica D Jensen (1) · Jianming Guo (1) · Klaus Brasso, MD (1)
PMID 23707439, PMID 24517338, PMID 25240974, PMID 26928245, PMID 27528718, PMID 27568654, PMID 27591931, PMID 28497198, PMID 31042111, PMID 31092381, PMID 31375469, PMID 31421657, PMID 31629656, PMID 32314028, PMID 34326126, PMID 36242700, PMID 36418170, PMID 36503429, PMID 37290915, PMID 38421252, PMID 39592501, PMID 41698328, PMID 41763960, PMID 41806372
2019 (1), U54CA302452 (1)